From <i>in silico</i> prediction to experimental validation: Identification of drugs and novel synergistic combinations that inhibit growth of inflammatory breast cancer cells.

ABSTRACT: Drug repurposing offers a promising approach for identifying novel treatments, especially for rare cancers like inflammatory breast cancer (IBC), an aggressive type with limited therapeutic options. Here, we present a comprehensive validation and verification study of compounds identified through two computational approaches: Literature Wide Association Studies (LWAS) and Gene Reversal Rate (GRR), using orthogonal cell viability assays in 2D models across IBC and non-IBC cell lines. In the SUM149 IBC cell line, repurposed compounds predicted from LWAS achieved a 70% success rate, with several showing nanomolar potency, while those predicted from GRR showed a 38% success rate. Through systematic combination screening in both 2D and 3D-spheroid models, we identified novel synergistic compoun

SUBMITTER: Salim EA 

PROVIDER: S-EPMC12713162 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature